Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Some medtech stocks did decline in 2018, but many more increased in value.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
Smaller transcatheter aortic valve groups face a tricky future.
Big cap medtech is hiring, largely thanks to organic growth.